Biotechnology
YS Biopharma Receives Additional 180 Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
GAITHERSBURG, Md., April 29, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious dise...
2024-04-29 20:00
979
WuXi AppTec Achieved First Quarter 2024 Target Despite External Challenges, Maintaining Stable Operations
* Revenue Reached RMB7,982 Million; Excluding COVID-19 Commercial Projects, Down 1.8% * Net Profit Attributable to the Owners of the Company Reached RMB1,942 Million; Diluted Earnings per Share (EPS) Reached RMB0.66 * Adjusted Non-IFRS Net Profit Attributable to the Owners of the Company Re...
2024-04-29 19:00
1562
Angel Yeast Publishes 2023 Corporate Social Responsibility Report
SHANGHAI, April 29, 2024 /PRNewswire/ -- Angel Yeast
2024-04-29 19:00
1291
DP Technology DevDay 2024 Showcases Large Science Models and Announces Open Science Initiative
BEIJING, April 29, 2024 /PRNewswire/ -- In recent years, the rapid development of artificial intelligence has introduced new possibilities across numerous scientific disciplines. As an AI for Science pioneer, DP Technology is continually collaborating with partners to explore the transformative i...
2024-04-29 15:31
868
Prota Therapeutics' CEO Mimi Tang honoured at BioMelbourne Network's Women in Leadership Awards 2024
MELBOURNE, Australia, April 29, 2024 /PRNewswire/ -- Prota Therapeutics' CEO ProfessorMimi Tang has been honoured in the prestigious 2024 BioMelbourne Network Women in Leadership Awards. Professor Tang's exceptional work as a lead researcher for the Murdoch Children's Research Institute (MCRI) an...
2024-04-29 10:40
1191
Ractigen Therapeutics Announces FDA Approval for RAG-01, a First-in-Class saRNA Therapy for BCG-Unresponsive NMIBC
SUZHOU, China, April 26, 2024 /PRNewswire/ -- Ractigen Therapeutics, a leader in the development of small activating RNA (saRNA) therapeutics, announced today that the U.S. Food and Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application for RAG-01, a grou...
2024-04-26 21:00
1134
Novel T-cell engager, CDH17 X CD3 cabotamig (ARB202) continues to explore dosing in patients with advanced gastrointestinal cancers
* The second DMC review recommends the continuation of dose escalation in the clinical trial as per protocol. * The interim safety assessment was based on the review of safety data from 18 metastatic gastrointestinal cancer patients, including patients that have tolerated multiple doses of ca...
2024-04-26 21:00
1190
Fosun Pharma's Self-developed Artemisinin Medicines Inject New Impetus to Malaria Prevention and Treatment in Africa
SHANGHAI, April 26, 2024 /PRNewswire/ -- World Malaria Day is marked each year onApril 25. World Health Organization (WHO) gave as the theme for World Malaria Day 2024Accelerating the fight against malaria for a more equitable world. WHO stated that malaria not only continues to directly endanger...
2024-04-26 12:39
1031
Hyosung TNC presents a new paradigm through sustainable bio BDO production.
SEOUL, South Korea, April 26, 2024 /PRNewswire/ -- Hyosung TNC is taking significant strides towards a sustainable future by focusing on the production of sustainable bio-based BDO. Butanediol (BDO) plays a crucial role as a chemical material not only in the production of spandex fibers like PTMG...
2024-04-26 08:00
1350
Caliway Announced CBL-514 Phase 2 Study for Cellulite Treatment Met All Primary and Secondary Endpoints
* CBL-514 is the first product to treat cellulite at the raised areas. * Currently, there is no effective and safe cellulite treatment on the market. The global market for cellulite treatment is estimated to expand to $7.37 billion in 2034. * CBL-0201EFP Phase 2 study demonstrated CBL-514 sta...
2024-04-26 01:25
1110
2024 ASCO | Mabwell to Present Clinical Data of 9MW2821 in Multiple Advanced Solid Tumor
SHANGHAI, April 25, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with an entire industry chain, announced that the Phase I/II clinical study results of the novel Nectin-4-targeting ADC 9MW2821 for multiple advanced solid tumors will be presented in an ...
2024-04-25 22:00
996
Hyundai Bioscience's antiviral for Dengue Fever to enter clinical trials in Brazil
* "Aiming to offer a Dengue antiviral treatment course in $100 price range" * Hyundai Bioscience decides to conduct dengue clinical trials in Brazil, which has the largest number of Dengue patients and offers a fast-track approval SEOUL, South Korea, April 25, 2024 /PRNewswire/ -- Hyundai Biosc...
2024-04-25 21:41
1144
Antengene Announces One Oral and Three Poster Presentations at ASCO 2024
* Oral session：ATG-008 (mTORC1/2 Inhibitor) combined with PD-1 antibody in Phase II studies for cervical cancer * Three Poster presentations: Phase I/II studies for ATG-031 (anti-CD24 monoclonal antibody) and ATG-022 (Claudin 18.2 antibody-drug conjugate) and selinexor(XPO1 Inhibitor) SHANGHA...
2024-04-25 20:00
1674
Onconic Therapeutics Receives MFDS Approval for JAQBO, a New Treatment for Gastroesophageal Reflux Disease (GERD)
SEOUL, South Korea, April 25, 2024 /PRNewswire/ -- Onconic Therapeutics, a leading biotechnology company in Korea, today announced that the Ministry of Food and Drug Safety (MFDS) of Korea has approved JAQBO (zastaprazan citrate) for the treatment of erosive gastroesophageal reflux disease (GERD)...
2024-04-25 19:57
1662
Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer
* The only solution for intractable cancer caused by mutations in the p53 gene * Planning clinical trials targeting cancer patients with no available treatment due to p53 gene mutations SEOUL, South Korea, April 25, 2024 /PRNewswire/ -- Hyundai Bioscience announced onApril 25th that its clinica...
2024-04-25 17:11
1024
GSK Advocates Importance of Adult Immunisation amongst Malaysians
KUALA LUMPUR, Malaysia, April 25, 2024 /PRNewswire/ -- As Malaysia's population shifts towards an ageing demographic, the importance of adult immunisation becomes increasingly apparent. By ensuring that individuals receive necessary vaccinations, adults can remain active, be healthy participants ...
2024-04-25 14:53
1316
PRISM BioLab, enters into a Joint Research and Licensing Agreement with Ono
PRISM BioLab will utilize PepMetics®, innovative small molecules that mimic three-dimensional structures of alpha-helix and beta-turns of peptidesfor drug discoveryagainst oncology target selected by Ono TOKYO, April 25, 2024 /PRNewswire/ -- PRISM BioLab, Co. Ltd. ("PRISM"), a leading discovery ...
2024-04-25 14:00
897
ASCO 2024 | Ascentage Pharma to Present Four Studies, Including an Oral Report Featuring the Latest Data of Olverembatinib in SDH-Deficient GIST
SUZHOU, China and ROCKVILLE, Md., April 24, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that results from four clinical studies of the co...
2024-04-25 09:02
1149
GenScript Biotech Releases 2023 ESG Report: Deepening Green Development Practices, Constructing Sustainable Future Blueprint
PISCATAWAY, N.J., April 24, 2024 /PRNewswire/ -- Recently, GenScript Biotech Corporation (HK.1548), a world leader in technologies and services for life science R&D and manufacture, released its 2023 Environmental, Social, and Governance (ESG) report. This report showcases the company's dedicated...
2024-04-24 22:31
1878
Breakthrough in Lung Cancer Treatment: Dizal to Unveil Groundbreaking Results of Sunvozertinib for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations at 2024 ASCO Annual Meeting
Topline results from Dizal's global pivotal phase II WU-KONG1 Part B study of sunvozertinib will be showcased in a featured oral presentation at the conference. SHANGHAI, April 24, 2024 /PRNewswire/ -- Dizal (SSE:688192), a biopharmaceutical company committed to developing groundbreaking new med...
2024-04-24 22:10
1279
Week's Top Stories
Most Reposted
Multiple achievements made in China-Hungary BRI conference
[Picked up by 319 media titles]
2024-05-03 06:59
Shanghai Jiao Tong University Offers Free Online Courses for International Learners, Joint Programs with Tmall of Alibaba and Dow Gain High Popularity
[Picked up by 317 media titles]
2024-05-07 08:00
VentureBlick Launches 'Discovery': The First Global Networking Platform for Healthcare Innovation
[Picked up by 312 media titles]
2024-05-08 14:37
OPTIX raises US$15 million fundraising to date to solve the bottleneck of XR optics technology
[Picked up by 306 media titles]
2024-05-08 08:00IN2MF in Kuala Lumpur Presented by Bank Indonesia
[Picked up by 290 media titles]
2024-05-08 16:44
Most Read
/C O R R E C T I O N -- Addverb/
2024-05-03 20:26
14378
Multiple achievements made in China-Hungary BRI conference
2024-05-03 06:59
9999
Xinhua president, Hungarian economy minister vow to bolster media cooperation
2024-05-03 06:25
9532
